卵母细胞基因表达系统的应用研究

目的 :建立研究神经生理及药理的卵母细胞表达模型 ,并对鸡脑mRNA在卵母细胞上表达的氨基酸类受体进行研究。方法 :采用盐酸胍或异硫氰酸胍法抽提总RNA ,经寡聚脱氧胸苷 (oligo -dT)纤维素柱纯化得mRNA。mRNA微注射到卵母细胞内进行表达 ,以双电极电压钳技术研究表达的受体。结果 :模型能明显表达外源性mRNA表达的受体 ,而阴性对照无表达。在卵母细胞膜上表达的γ -氨基丁酸 (γ -aminobutyricacid ,GABA) ,甘氨酸(Glycine ,Gly)及红藻氨酸 (Kainate ,KA)受体 ,施加GABA ,Gly及KA均能引起一剂量依赖的内向电流 ,相应的拮抗剂可阻断其电流。剂量效应曲线显示GABA及KA诱导电流的半有效浓度 (EC5 0 )分别为 2 .9× 10 -5mol/L及 6 .3× 10 -5mol/L。结论 :卵母细胞可明显表达鸡脑mRNA编码的KA ,Gly及GABA受体 ,其药理特性与天然受体相似 ,是一个良好的神经生理及药理研究模型。     

青海省甘德县人群包虫病流行病学调查

用Ｄｏｔ－ＥＬＩＳＡ和Ｂ超、Ｘ线在果洛州甘德县进行了人群包虫病的流行病学调查。结果表明,人群包虫病血清阳性率为１０．８３％。男性和女性分别为９．２９％和１２．９２％。Ｂ超、Ｘ线检查阳性率为５．７７％,男性和女性分别为４．８３％和７．０５％。女性高于男性不同职业血清阳性率和Ｂ超、Ｘ线检查阳性率均以牧民最高（１７．５６＾和１１．５６％）随年龄增加,人群包虫病血清阳性率和Ｂ超、Ｘ线检查阳性率越高。不同地     

临床常用药物对人体酸碱平衡的影响

目的：探讨临床常用药物对人体酸碱平衡的影响,指导临床工作。方法：用酸度计测定九种药品ｐＨ值,计算氢离子浓度。结果：偏碱性的药物有５０ｇ／Ｌ碳酸氢钠,谷氨酸钠、谷氨酸钾注射液;偏酸性的药物有盐酸精氨酸、维生素Ｃ、各种浓度葡萄糖注射液、氯化钠注射液。结论：临床上一些常用药品会影响人体的酸碱平衡,尤其在机体酸碱平衡调节发生障碍的情况下,更应谨慎。     

乙型肝炎患者血清丁型肝炎病毒标志的研究

目的 研究ＨＤＶ重叠ＨＢＶ感染对乙型肝炎患者病情和血清学指标的影响。方法 采用ＥＬＩＳＡ法检测ＨＤＶ血清标志ＨＤＡｇ、抗ＨＤ、抗ＨＤＩｇＭ和ＨＢＶ血清标志ＨＢｓＡｇ、抗ＨＢｓ、ＨＢｅＡｇ、抗ＨＢｃ、抗ＨＢｃｌｇＭ,ＰＣＲ法检测ＨＢＶＤＮＡ。结果 ３１６例乙型病毒性肝炎中６０例重叠ＨＤＶ感染,重叠感染率为１８．９８％;ＣＨ和ＦＨ组ＨＤＶ感染率显著高于ＡＨ,ＦＨ组ＨＤＶ复制指标阳性率显著高于ＣＨ及ＡＨ     

急性坏死型胰腺炎的B超与CT诊断比较(附38例分析)

目的 评价超声及ＣＴ诊断急性坏死型胰腺炎（ＡＮＰ）的价值。方法 将３８例急性胰腺炎患者手术前的超声及ＣＴ诊断资料与手术病理诊断进行对照,分析超声及ＣＴ诊断ＡＮＰ的敏感性、特异性、预测精确性。结果 ３８例患者,按手术病理诊断,３０例为ＡＮＰ,７例为急性水肿型胰腺炎,１例化脓性胆囊炎胰腺未见异常。ＣＴ诊断ＡＮＰ的敏感性９５．８％,特异性８０．０％,阳性预测值９５．８％,阴笥预测值８０．０％,预测精确性     

A Phase 2 open label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infection

Retrospective data showed that when we administered ledipasvir/sofosbuvir (LDV/SOF) to patients with hepatitis B and C coinfection, there was a modest reduction in hepatitis B surface antigen (HBsAg). Therefore, we hypothesize that similar HBsAg reduction can be seen in hepatitis B virus (HBV) monoinfected subjects. Primary and secondary efficacy endpoints are the decline in HBsAg and HBV DNA at Week 12 from baseline, respectively. We conducted an open-label Phase 2 pilot study to evaluate the safety, tolerability, and antiviral activity of LDV and/or SOF for HBV. Eligible subjects were either suppressed on antivirals (Group B) or inactive chronic HBV (Group A, C, D). Group A and B received LDV/SOF. Group C and D received SOF 400 mg and LDV 90 mg, respectively. All subjects completed the study, and all related adverse events (AEs) were mild. No discontinuations due to AEs or hepatitis flare occurred. At Week 12, HBsAg decline (log₁₀ IU/ml) was similar between Group A (0.399) and B (0.400), less in Group C (0.207), and none in Group D, and there was HBV DNA decline in the inactive chronic HBV groups. LDV and SOF are safe and well tolerated when given to chronic hepatitis B subjects and have modest antiviral activity, particularly when given in combination.     

Decreased frequency of a novel T-lymphocyte subset,CD3+CD4−CD7+CD57− T cells,in hepatitis B virus-related end-stage liver disease might contribute to disease progression

CD7 and CD57 are related to the differentiation and functional stages of CD8⁺ T cells. However, the role of their combined presence in CD8⁺ T cells in patients with chronic hepatitis B virus (HBV) infection, especially those with end-stage liver disease, remains unclear. Blood samples from healthy volunteers and patients with chronic hepatitis B were analyzed via Luminex assay and ELISA to measure plasma cytokine levels. Further, recombinant IL-22 was used to stimulate peripheral blood mononuclear cells from healthy volunteers, and the frequency of CD3⁺CD4⁻CD7⁺CD57⁻ T cells and apoptosis rates were investigated via flow cytometry. Patients with end-stage liver disease, particularly those with acute to chronic liver failure, showed decreased CD3⁺CD4⁻CD7⁺CD57⁻ T cell frequency. Furthermore, the prevalence of CD3⁺CD4⁻CD7⁺CD57⁻ T cells was negatively correlated with disease severity, prognosis, and complications (ascites). We also observed that IL-22 promoted apoptosis and brought about a decrease in the number of CD3⁺CD4⁻CD7⁺CD57⁻ T cells in a dose-dependent manner. CD3⁺CD4⁻CD7⁺CD57⁻ T cells displayed a B and T lymphocyte attenuator (BTLA)^highCD25^highCD127^high immunosuppressive phenotype and showed low interferon-γ, tumor necrosis factor-α, granzyme A, and perforin expression levels. The present findings will elucidate the pathogenesis of HBV-related end-stage liver disease and aid the identification of novel drug targets.     

The third inactivated vaccine booster dramatically enhanced SARS-CoV-2 antibody responses and did not influence the profile of prothrombotic antibody

The purpose of this study is to investigate the production of both severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-specific antibodies and autoantibodies in serum following the third booster vaccination of the inactivated COVID-19 vaccine, and to study the effect of B cell subsets with CD27 and CD38 phenotypes in peripheral blood on antibody production. Routine blood indexes, SARS-CoV-2 antibodies, platelet factor 4 and seven antiphospholipid antibodies were detected both before and 2 months after vaccination in the medical staff of the Zhongnan Hospital of Wuhan University. Peripheral blood B cell subtypes were detected before vaccination. Following immunization, the positive rate of anti-N-S1 immunoglobulin (IgG) had increased from 24.8% to 91.3% and the average antibody concentration had increased by 11 times. The positive rate of neutralizing antibody had increased from 24.8% to 91.3%, the average antibody concentration had increased by 12 times, and the primary increased anti-S1 IgG subtype was that of IgG1. Peripheral blood CD27 + CD38+ B cells were positively correlated with antibody levels after vaccination and were a predictor of the antibody response. In addition, although some indicators showed slight absolute changes, the blood parameters and antiphospholipid antibodies of most volunteers were normal both before and after COVID-19 inactivated vaccine inoculation, and there was no statistical difference in abnormal rates either before or after inoculation. Antibodies in vivo were increased after vaccination with the inactivated vaccine, and IgG1 was the main subtype involved in response to the vaccine. Vaccination with the inactivated COVID-19 vaccine did not appear to affect thrombus-related autoantibodies.